Enveloped Nanoparticle Self-Assembly for Scalable RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing cell-derived extracellular vesicles (EVs) for nucleic acid delivery face challenges such as low production rates, toxicity issues, and difficulty in engineering specific surface markers and encapsulating therapeutic cargoes, limiting their feasibility for large-scale production and targeted delivery.
Innovation Solution
The development of self-assembling enveloped nanoparticles (ENPs) using a fusion protein comprising a cell-surface protein (CSP), RNA-binding protein (RBP), and endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD), which self-assemble into nanoparticles capable of encapsulating cargo RNA molecules and are secreted from cells, enabling efficient and non-toxic large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell-derived extracellular vesicles (EVs) are used for nucleic acid delivery, then targeting capability and biocompatibility are improved, but production rate is low and scalability is limited
Solution Approach 1:
The patent creates artificial copies of natural EV structures by using engineered nanoparticles that mimic the targeting and biocompatibility features of EVs without requiring cellular production. The ENPs copy the essential functional elements (surface markers, nucleic acid encapsulation) while eliminating the production bottleneck of cellular EV secretion
Solution Approach 2:
The patent changes the production parameter from cellular secretion (low rate, hard to control) to chemical self-assembly (high rate, controllable). By transforming the production mechanism from biological to chemical/physical, the system achieves scalable production while maintaining the desired targeting properties through engineered surface modifications
2Productivity
If chemical and physical methods are used to increase EV production, then production rate is improved, but cell toxicity increases
Solution Approach 1:
Instead of forcing cells to produce more EVs through toxic stimulation, the patent copies the EV structure and function using non-cellular self-assembling nanoparticles. This eliminates the need for toxic production enhancement methods while achieving high production rates through scalable chemical processes
Solution Approach 2:
The patent introduces an intermediary self-assembly process that bridges the gap between desired high production rates and cell safety. Rather than directly stimulating cells (which causes toxicity), the system uses controlled chemical self-assembly as an intermediary mechanism to produce EV-like particles without cellular stress
3Manufacturing precision
If EVs are engineered to display specific surface markers and encapsulate therapeutic cargoes, then targeting precision is improved, but engineering complexity increases
Solution Approach 1:
The patent segments the EV engineering process into modular components: the nanoparticle core for encapsulation, separate surface modification steps for targeting markers, and independent cargo loading. This segmentation allows each function to be optimized separately and assembled systematically, reducing overall engineering complexity
Solution Approach 2:
The patent performs preliminary actions by pre-equipping the nanoparticle system with modular surface marker components and encapsulation capabilities before final assembly. The self-assembling nature of ENPs allows pre-programmed targeting sequences and cargo compartments to be integrated automatically, reducing the complexity of post-assembly engineering
4Productivity
If self-assembling enveloped nanoparticles (ENPs) are used instead of EVs, then production scalability is improved, but need for validation of biological functionality arises
Solution Approach 1:
The patent changes the production parameters to enable scalability (chemical self-assembly, controlled environment, standardized protocols) while systematically validating biological functionality through defined assays. The controlled parameter changes allow for consistent quality control and functional verification across large-scale production
Solution Approach 2:
The patent implements feedback mechanisms to validate biological functionality at multiple stages: characterization of self-assembly properties, verification of cargo encapsulation efficiency, assessment of cellular uptake and targeting, and evaluation of therapeutic effect. This multi-stage feedback ensures biological functionality is maintained despite the shift from cellular to chemical production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ENPs provide a scalable and non-toxic method for producing nanoparticles that efficiently encapsulate and deliver nucleic acid cargoes, enhancing bioavailability and targeting therapeutic payloads to disease-specific tissues while minimizing adverse effects.
Implementation Method 1
the RBP is capable of binding the packing signal
Implementation Method 2
a plurality of fusion proteins are capable of self-assembling into an enveloped nanoparticle (ENP)
Implementation Method 3
recruits cellular proteins from the Endosomal Sorting Complex Required for Transport (ESCRT) pathway to induce ENP budding and release
Data Source
AI summary
Disclosed herein include methods, compositions, and kits suitable for use in e.g., nucleic acid delivery. Provided are compositions (e.g., nucleic acid compositions) comprising polynucleotide(s) encoding a fusion protein, a dimerization fusion protein, a soluble RBP, an adapter fusion protein, and/or a cell fusion protein. The compositions also comprise one or more polynucleotides comprising one or more RNA cargo molecules. The fusion protein, dimerization fusion protein, and/or adapter fusion protein can comprise an endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD). Recruitment of one or more ESCRT proteins results in secretion of enveloped nanoparticles (ENPs) from a cell in which at least one of a fusion protein, a dimerization fusion protein, and/or an adapter fusion protein are expressed. The ENPs can comprise the one or more RNA cargo molecules. There are also provided populations of ENPs in some embodiments.